| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
|
J Clin Oncol
|
2009
|
14.15
|
|
2
|
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
|
J Clin Oncol
|
2007
|
2.62
|
|
3
|
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
|
Clin Cancer Res
|
2005
|
2.46
|
|
4
|
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
|
Clin Cancer Res
|
2006
|
2.44
|
|
5
|
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
|
Neurology
|
2004
|
2.41
|
|
6
|
Patterns of care in elderly glioblastoma patients.
|
Ann Neurol
|
2008
|
2.17
|
|
7
|
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
|
Int J Radiat Oncol Biol Phys
|
2009
|
2.07
|
|
8
|
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
|
Neuro Oncol
|
2011
|
1.95
|
|
9
|
The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.
|
Cancer
|
2004
|
1.81
|
|
10
|
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.
|
J Clin Oncol
|
2006
|
1.74
|
|
11
|
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
|
Cancer
|
2005
|
1.69
|
|
12
|
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
|
Neuro Oncol
|
2009
|
1.66
|
|
13
|
Intracranial dural metastases.
|
Cancer
|
2009
|
1.59
|
|
14
|
International study on low-grade primary central nervous system lymphoma.
|
Ann Neurol
|
2006
|
1.59
|
|
15
|
Advancing the treatment of malignant glioma: act local, think global.
|
Cancer Invest
|
2004
|
1.59
|
|
16
|
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
|
J Clin Oncol
|
2009
|
1.58
|
|
17
|
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
|
J Clin Oncol
|
2013
|
1.54
|
|
18
|
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
|
Neuro Oncol
|
2011
|
1.53
|
|
19
|
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
|
Neuro Oncol
|
2010
|
1.46
|
|
20
|
Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report.
|
Blood
|
2007
|
1.46
|
|
21
|
Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy.
|
Leuk Lymphoma
|
2011
|
1.45
|
|
22
|
Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group.
|
J Clin Oncol
|
2005
|
1.44
|
|
23
|
Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma.
|
Neurology
|
2007
|
1.43
|
|
24
|
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.
|
J Neurooncol
|
2012
|
1.42
|
|
25
|
Maintenance therapy for central nervous system lymphoma with rituximab.
|
Leuk Lymphoma
|
2009
|
1.39
|
|
26
|
Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002.
|
J Clin Oncol
|
2003
|
1.39
|
|
27
|
Capecitabine therapy of central nervous system metastases from breast cancer.
|
J Neurooncol
|
2007
|
1.37
|
|
28
|
Therapeutic challenges in primary CNS lymphoma.
|
Lancet Neurol
|
2009
|
1.36
|
|
29
|
Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy.
|
J Neurooncol
|
2008
|
1.36
|
|
30
|
Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007).
|
Cancer
|
2009
|
1.35
|
|
31
|
Delayed neurotoxicity in primary central nervous system lymphoma.
|
Arch Neurol
|
2005
|
1.35
|
|
32
|
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).
|
J Neurooncol
|
2008
|
1.31
|
|
33
|
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
|
Neuro Oncol
|
2009
|
1.30
|
|
34
|
Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches.
|
Radiat Oncol
|
2011
|
1.29
|
|
35
|
Cognitive functions in primary CNS lymphoma after single or combined modality regimens.
|
Neuro Oncol
|
2011
|
1.25
|
|
36
|
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
|
J Neurooncol
|
2009
|
1.21
|
|
37
|
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
|
Neuro Oncol
|
2002
|
1.20
|
|
38
|
Primary dural lymphomas: a review.
|
Neurosurg Focus
|
2006
|
1.19
|
|
39
|
Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.
|
Curr Neurol Neurosci Rep
|
2013
|
1.16
|
|
40
|
Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis.
|
Cancer
|
2005
|
1.15
|
|
41
|
Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study.
|
Neurology
|
2004
|
1.15
|
|
42
|
Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients.
|
Neurology
|
2006
|
1.14
|
|
43
|
Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience.
|
Cancer
|
2010
|
1.11
|
|
44
|
Systemic high-dose intravenous methotrexate for central nervous system metastases.
|
J Neurooncol
|
2006
|
1.11
|
|
45
|
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.
|
Neuro Oncol
|
2010
|
1.08
|
|
46
|
Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older.
|
Cancer
|
2012
|
1.08
|
|
47
|
Primary central nervous system lymphoma.
|
Neurol Clin
|
2007
|
1.07
|
|
48
|
The utility of body FDG PET in staging primary central nervous system lymphoma.
|
Neuro Oncol
|
2008
|
1.07
|
|
49
|
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
|
Oncologist
|
2010
|
1.05
|
|
50
|
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
|
Neuro Oncol
|
2012
|
1.04
|
|
51
|
Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG).
|
Clin Cancer Res
|
2011
|
1.04
|
|
52
|
Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
|
J Neurosurg
|
2002
|
1.03
|
|
53
|
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
|
J Neurooncol
|
2006
|
1.02
|
|
54
|
Central nervous system lymphoma.
|
Hematology Am Soc Hematol Educ Program
|
2002
|
1.02
|
|
55
|
Current management of metastatic brain disease.
|
Neurotherapeutics
|
2009
|
1.01
|
|
56
|
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.
|
Neuro Oncol
|
2011
|
1.00
|
|
57
|
Bcl-6 predicts improved prognosis in primary central nervous system lymphoma.
|
Cancer
|
2008
|
0.99
|
|
58
|
Longitudinal cognitive follow-up in low grade gliomas.
|
J Neurooncol
|
2007
|
0.97
|
|
59
|
Cognitive functions in low-grade gliomas: disease and treatment effects.
|
J Neurooncol
|
2006
|
0.96
|
|
60
|
Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
|
J Neurooncol
|
2002
|
0.96
|
|
61
|
Salvage temozolomide for prior temozolomide responders.
|
Cancer
|
2005
|
0.95
|
|
62
|
Intracranial hemorrhage in patients treated with bevacizumab and low-molecular weight heparin.
|
Clin Adv Hematol Oncol
|
2007
|
0.95
|
|
63
|
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
|
Neuro Oncol
|
2009
|
0.94
|
|
64
|
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma.
|
Ann Neurol
|
2011
|
0.94
|
|
65
|
Initial treatment patterns over time for anaplastic oligodendroglial tumors.
|
Neuro Oncol
|
2012
|
0.92
|
|
66
|
Diagnosis and management of primary intraocular lymphoma: an update.
|
Clin Ophthalmol
|
2007
|
0.92
|
|
67
|
Late relapse in primary central nervous system lymphoma: clonal persistence.
|
Neuro Oncol
|
2011
|
0.92
|
|
68
|
Neurological outcome of long-term glioblastoma survivors.
|
J Neurooncol
|
2009
|
0.92
|
|
69
|
Imaging of lymphoma of the central nervous system, spine, and orbit.
|
Radiol Clin North Am
|
2008
|
0.89
|
|
70
|
CNS Hodgkin lymphoma.
|
Blood
|
2008
|
0.89
|
|
71
|
Prognosis and patterns of care in elderly patients with glioma.
|
Cancer
|
2009
|
0.89
|
|
72
|
Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.89
|
|
73
|
Patterns of treatment in older adults with primary central nervous system lymphoma.
|
Cancer
|
2007
|
0.89
|
|
74
|
Chemotherapy for primary central nervous system lymphoma.
|
Neurosurg Focus
|
2006
|
0.88
|
|
75
|
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium.
|
Neuro Oncol
|
2008
|
0.88
|
|
76
|
Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.
|
Leuk Lymphoma
|
2012
|
0.87
|
|
77
|
Leukemic and lymphomatous meningitis: incidence, prognosis and treatment.
|
J Neurooncol
|
2005
|
0.87
|
|
78
|
New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting.
|
Clin Cancer Res
|
2005
|
0.87
|
|
79
|
Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.
|
Cancer
|
2008
|
0.87
|
|
80
|
Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma.
|
Cancer
|
2007
|
0.86
|
|
81
|
Bevacizumab in recurrent malignant glioma.
|
Curr Neurol Neurosci Rep
|
2008
|
0.85
|
|
82
|
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.
|
J Neurooncol
|
2007
|
0.85
|
|
83
|
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas.
|
J Neurooncol
|
2011
|
0.85
|
|
84
|
Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas.
|
Target Oncol
|
2010
|
0.84
|
|
85
|
A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
|
J Neurooncol
|
2008
|
0.84
|
|
86
|
Diagnosis and treatment of primary central nervous system lymphoma.
|
Curr Oncol Rep
|
2005
|
0.83
|
|
87
|
Primary central nervous system lymphoma.
|
Curr Oncol Rep
|
2004
|
0.81
|
|
88
|
Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up.
|
Neurology
|
2005
|
0.81
|
|
89
|
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.
|
J Neurooncol
|
2007
|
0.80
|
|
90
|
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
|
Neuro Oncol
|
2004
|
0.79
|
|
91
|
Utility of brain FDG-PET in primary CNS lymphoma.
|
Clin Adv Hematol Oncol
|
2008
|
0.79
|
|
92
|
Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium.
|
Clin Cancer Res
|
2002
|
0.79
|
|
93
|
Radiotherapy and temozolomide for anaplastic astrocytic gliomas.
|
J Neurooncol
|
2015
|
0.79
|
|
94
|
Response of glioblastomas to EGFR kinase inhibitors.
|
N Engl J Med
|
2006
|
0.78
|
|
95
|
Post-treatment T1 shortening in primary CNS lymphoma.
|
J Neurooncol
|
2012
|
0.78
|
|
96
|
Retinopathy in survivors of primary central nervous system lymphoma.
|
Neurology
|
2006
|
0.78
|
|
97
|
Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma.
|
Leuk Lymphoma
|
2008
|
0.78
|
|
98
|
Synchronous presentation of systemic and brain non-Hodgkin lymphoma.
|
Leuk Lymphoma
|
2008
|
0.77
|
|
99
|
Chemotherapy for brain metastases: breast, gynecologic and non-melanoma skin malignancies.
|
Cancer Treat Res
|
2007
|
0.77
|
|
100
|
Leptomeningeal metastases from leukemias and lymphomas.
|
Cancer Treat Res
|
2005
|
0.77
|
|
101
|
A phase II trial of oral gimatecan for recurrent glioblastoma.
|
J Neurooncol
|
2012
|
0.76
|
|
102
|
High-grade gliomas in patients with prior systemic malignancies.
|
Cancer
|
2002
|
0.76
|
|
103
|
Chemotherapy and the treatment of brain metastases.
|
Hematol Oncol Clin North Am
|
2006
|
0.76
|
|
104
|
Magnetic resonance spectroscopy imaging in radiotherapy planning for recurrent glioma.
|
Med Phys
|
2011
|
0.76
|
|
105
|
Primary central nervous system lymphoma.
|
Semin Radiat Oncol
|
2007
|
0.76
|
|
106
|
Should patients with anaplastic oligodendroglial tumors receive adjuvant chemotherapy?
|
Nat Clin Pract Oncol
|
2007
|
0.75
|
|
107
|
Imaging neurotoxicity: is a picture worth a thousand words?
|
AJNR Am J Neuroradiol
|
2005
|
0.75
|
|
108
|
Anaplastic oligodendroglioma.
|
Curr Neurol Neurosci Rep
|
2007
|
0.75
|
|
109
|
Management of primary central nervous system lymphoma.
|
J Natl Compr Canc Netw
|
2004
|
0.75
|
|
110
|
Pharmacotherapy of primary CNS lymphoma.
|
Expert Opin Pharmacother
|
2002
|
0.75
|
|
111
|
Brain metastases: old problem, new strategies.
|
Hematol Oncol Clin North Am
|
2007
|
0.75
|
|
112
|
Unraveling molecular markers of biologic therapies in glioma.
|
Curr Neurol Neurosci Rep
|
2006
|
0.75
|
|
113
|
Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: preliminary findings.
|
Clin Adv Hematol Oncol
|
2003
|
0.75
|
|
114
|
Update on the therapeutic approaches to brain tumors.
|
Expert Rev Anticancer Ther
|
2003
|
0.75
|